Inhibition of human cytochromes P450 by components of Ginkgo biloba

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 8, 2004, Pages 1039-1044

  von Moltke, Lisa L ^a   Weemhoff, James L ^a   Bedir, Erdal ^b,c   Khan, Ikhlas A ^b   Harmatz, Jerold S ^a   Goldman, Peter ^d   Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c EGE UNIVERSITY   (Turkey)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NONADEC 8 ENYLBENZENE 1,2 DIOL; 4' O METHYL APIGENIN; 4,4' (1,4 PENTADIENE 1,5 DIYL)DIPHENOL; AMENTOFLAVONE; APIGENIN; BILOBALIDE; BILOBETIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; CYTOCHROME P450 ISOENZYME; FLAVONE DERIVATIVE; FLAVONOID GLYCOSIDE; FLAVONOL DERIVATIVE; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; GINKGOLIDE J; KAEMPFEROL; KAEMPFEROL GLYCOSIDE; LACTONE DERIVATIVE; LUTEOLIN GLYCOSIDE; MYRICETIN; QUERCETIN; QUERCETIN GLYCOSIDE; SESAMIN; TAMARIXETIN; TERPENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER MICROSOME;

CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GINKGO BILOBA; HUMANS; ISOENZYMES; MICROSOMES, LIVER; PLANT EXTRACTS;

EID: 4344616168     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357044021     Document Type: Article

References (43)

1. Bedir, E., Tatli, I. I., Khan, R. A., Zhao, J., Takamatsu, S., Walker, L. A., Goldman, P., Khan, I. A. (2002) Biologically active secondary metabolites from Ginkgo biloba. J. Agric. Food Chem. 50: 3150-3155
2. Bertz, R. J., Granneman, G. R. (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 32: 210-258
3. Bjornsson, T. D., Callaghan, J. T., Einolf, H. J., Fischer, V., Gan, L., Grimm, S., Kao, J., King, S. P., Miwa, G., Ni, L., Kumar, G., McLeod, J., Obach, S. R., Roberts, S., Roe, A., Shah, A., Snikeris, F., Sullivan, J. T., Tweedie, D., Vega, J. M., Walsh, J., Wrighton, S. A. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J. Clin. Pharmacol. 43: 443-469
4. de Smet, P. A. (2002) Herbal remedies. N. Engl. J. Med. 347: 2046-2056
5. Eisenberg, D. M., Davis, R. B., Ettner, S. L., Appel, S., Wilkey, S., Van Rompay, M., Kessler, R. C. (1998) Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280: 1569-1575
6. Engelsen, J., Nielsen, J. D., Winther, K. (2002) Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb. Haemost. 87: 1075-1076
7. Ernst, E. (2002) The risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and Kava. Ann. Intern. Med. 136: 42-53
8. Fugh-Berman, A. (2000) Herb-drug interactions. Lancet 355: 134-138
9. Giancarlo, G. M., Venkatakrishnan, K., Granda, B. W., von Moltke, L. L., Greenblatt, D. J. (2001) Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole and ticlopidine. Eur. J. Clin. Pharmacol. 57: 31-36
10. Goldman, P. (2001) Herbal medicines today and the roots of modern pharmacology. Ann. Intern. Med. 135: 594-600
11. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., Gentry, W. B., Cui, Y., Ang, C. Y. (2002) Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther. 72: 276-287
12. He, N., Edeki, T. (2002) Effects of ginseng and Ginkgo biloba components on CYP2C9 mediated tolbutamide 4-methyl-hydroxylation in human liver microsomes (abstract). Clin. Pharmacol. Ther. 71: P67
13. Heck, A. M., DeWitt, B. A., Lukes, A. L. (2000) Potential interactions between alternative therapies and warfarin. Am. J. Health. Syst. Pharm. 57: 1221-1227
14. Izzo, A. A., Ernst, E. (2001) Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61: 2163-2175
15. Kaminsky, L. S., Zhang, Z.-Y. (1997) Human P450 metabolism of warfarin. Pharmacol. Ther. 73: 67-74
16. Kressmann, S., Muller, W. E., Blume, H. H. (2002) Pharmaceutical quality of different Ginkgo biloba brands. J. Pharm. Pharmacol. 54: 661-669
17. Lai, C.-F., Chang, C.-C., Fu, C.-H., Chen, C.-M., Chen, H.-Y. (2002) Evaluation of the interaction between warfarin and Ginkgo biloba extract (abstract). Pharmacotherapy 22: 1326
18. MacLennan, K. M., Darlington, C. L., Smith, P. F. (2002) The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog. Neurobiol. 67: 235-257
19. Markowitz, J. S., Donovan, J. L., DeVane, C. L., Sipkes, L., Chavin, K. D. (2003) Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J. Clin. Psychopharmacol. 23: 576-581
20. Matthews, M. K. (1998) Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 50: 1933-1934
21. Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., Traeger, W. F. (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem. Res. Toxicol. 5: 54 59
22. Scalbert, A., Williamson, G. (2000) Dietary intake and bioavailability of polyphenols. J. Nutr. 130: 2073S-2085S
23. Schulz, V., Hänsel, R., Tyler, V. E. (2001) Rational phytotherapy: a physician's guide to herbal medicine. Springer-Verlag, Berlin, pp. 41-56
24. Smith, M., Lin, K. M., Zheng YP (2001) An open trial of nifedipine-herb interactions: nifedipine with St. John's wort, ginseng, or Ginkgo biloba (abstract). Clin. Pharmacol. Ther. 69: P86
25. Sun, H., Zuo, Z., Yin, O. Q., Tomlinson, B., Chow, M. S. (2002) A high-throughput cocktail method for screening the effect of herbal product on liver isozyme activities: experience with Ginkgo biloba (abstract). Clin. Pharmacol. Ther. 71: P100
26. Vaes, L. P., Chyka, P. A. (2000) Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann. Pharmacother. 34: 1478-1482
27. Valli, G., Giardina, E. G. (2002) Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J. Am. Coll. Cardiol. 39: 1083-1095
28. van Beek, T. A. (2002) Chemical analysis of Ginkgo biloba leaves and extracts. J. Chromatog. A 967: 21-55
29. Venkatakrishnan, K., von Moltke, L. L., Greenblatt, D. J. (1998a) Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. J. Pharm. Sci. 87: 1502-1507
30. Venkatakrishnan, K., von Moltke, L. L., Greenblatt, D. J. (1998b) Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. J. Pharm. Sci. 87: 845-853
31. Venkatakrishnan, K., von Moltke, L. L., Greenblatt, D. J. (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J. Clin. Pharmacol. 41: 1149-1179
32. Venkatakrishnan, K., von Moltke, L. L., Obach, R. S., Greenblatt, D. J. (2003) Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr. Drug Metab. 4: 423-459
33. von Moltke, L. L., Greenblatt, D. J., Harmatz, J. S., Shader, R. I. (1993) Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47: 268-276
34. von Moltke, L. L., Greenblatt, D. J., Duan, S. X., Schmider, J., Kudchadker, L., Fogelman, S. M., Harmatz, J. S., Shader, R. I. (1996a) Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology 128: 398-407
35. von Moltke, L. L., Greenblatt, D. J., Harmatz, J. S., Duan, S. X., Harrel, L. M., Cotreau-Bibbo, M. M., Pritchard, G. A., Wright, C. E., Shader, R. I. (1996b) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J. Pharmacol. Exp. Ther. 276: 370-379
36. von Moltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W., Duan, S. X., Fogelman, S. M., Daily, J. P., Harmatz, J. S., Shader, R. I. (1998a) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J. Clin. Pharmacol. 38: 106-111
37. von Moltke, L. L., Greenblatt, D. J., Grassi, J. M., Granda, B. W., Venkatakrishnan, K., Schmider, J., Harmatz, J. S., Shader, R. I. (1998b) Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J. Pharm. Pharmacol. 50: 997-1004
38. von Moltke, L. L., Greenblatt, D. J., Schmider, J., Wright, C. E., Harmatz, J. S., Shader, R. I. (1998c) In vitro approaches to predicting drug interactions in vivo. Biochem. Pharmacol. 55: 113-122
39. von Moltke, L. L., Weemhoff, J. L., Perloff, M. D., Hesse, L. M., Harmatz, J. S., Roth-Schechter, B. F., Greenblatt, D. J. (2002) Effect of zolpidem on human Cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm. Drug Dispos. 23: 361-367
40. Weinges, K., Hepp, M., Huberpatz, U., Rodewald, H., Irngartinger, H. (1986) Chemistry of ginkgolides. 1. 10-acetyl-1-methoxycarbonyl-2.3, 14, 15, 16-pentanorginkgolide-A, an intermediate for the synthesis of bilobalide. Liebigs Ann. Chem. 6: 1057-1066
41. Yu, F.-C., Lai, S.-M., Suen, S.-Y. (2003) Extraction of flavonoid glycosides from Ginkgo biloba leaves and their adsorption separations using hydrophobic and anion-exchange membranes. Separation Sci. Technol. 38: 1022-1050
42. Zhou, S., Gao, Y., Jiang, W., Huang, M., Xu, A., Paxton, J. W. (2003) Interactions of herbs with cytochrome P450. Drug Metab. Rev. 35: 35-98
43. Zou, L., Harkey, M. R., Henderson, G. L. (2002) Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 71: 1579-1589